𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

✍ Scribed by U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppä; R. Marttila; B. Mikkelsen; H. Pakkenberg; J. Presthus

Publisher
Springer
Year
1975
Tongue
English
Weight
528 KB
Volume
211
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

✦ Synopsis

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide proved superior to levodopa on several accounts. Nausea and vomiting occurred with statistically significant less severity and frequency. Clinical improvement expressed through improvement in Webster rating occurred sooner and was all together greater. The treatment schedules did not differ with regard to other side effects, in particular involuntary movements and reduction in supine blood pressure. Neither treatment seemed to influence liver function, renal function and hematological parameters.

📜 SIMILAR VOLUMES

Levodopa in the treatment of Parkinson's
Levodopa in the treatment of Parkinson's disease: Current controversies
✍ C. Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; U. Bonucelli; Phili 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the “gold standard” against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor

Levodopa “drug holiday” with amantadine
Levodopa “drug holiday” with amantadine infusions as a treatment of complications in Parkinson's disease
✍ Dariusz Koziorowski; Andrzej Friedman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The loss of beneficial effect of levodopa due to progression of the disease and alteration of receptor sensitivity makes the treatment of the advanced stadium of Parkinson's disease (PD) very difficult. In the past “drug holidays” was used in attempt to resensitize dopamine receptors in

Effect of entacapone, a COMT inhibitor,
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari